PLA2G4A and Alzheimer disease: Among the five compounds, bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-,[1R-(1R∗,4Z,9S∗)] exhibited significant binding efficacy with PTGS2 and PLA2G4A, displaying higher binding energy compared to their respective controls, indicating their potential in AD treatment.